Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

NCI study showing 85% of PSMA-positive BCR patients avoid treatment with surveillance approach, PSMA PET in Biochemical Recurrence: When to Treat vs When to Wait with Ravi Madan, tian zhang.

ENZAMET study, IGF-1 cytokines and sphingolipids as prognostic factors in mHSPC, precision metabolic therapy trials, Exploring IGF-1 Pathway Biomarkers and Outcomes in Metastatic Hormone-Sensitive ...

In [18F]F-PSMA-1007 PET imaging, focal bone uptake without morphological correlate (MC) on CT, is often classified as benign. In [68Ga]Ga-PSMA-11, intense focal uptake without MC in a classical ...

Trimodality therapy (TMT), consisting of maximal transurethral resection of bladder tumor (TURBT) followed by concurrent chemoradiotherapy, has emerged as a bladder-sparing alternative to radical ...

Neeraj Agarwal is joined by Zeynep Ozay to discuss a comparative effectiveness study of lutetium-177 versus cabazitaxel in metastatic castration-resistant prostate cancer. Using the nationwide ...

The EORTC 1333 'PEACE-3' study investigated the combination of enzalutamide and 6 monthly injections of radium-223 (Ra223) in patients with metastatic castration-resistant prostate cancer (mCRPC) and ...

PDIGREE phase III adaptive, enrolled 1000+ metastatic kidney cancer patients across 500+ sites, ASCO 2025 results and innovative treatment strategies, PDIGREE Trial Tests Adaptive Immunotherapy ...

(UroToday.com) The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, held in Washington D.C., United States, was host to the session: BCAN 2023 Bladder Cancer Research Innovation ...